LYST, VIDAZA and CC-486. Additional collaborations with Juno Therapeutics, Inc. and bluebird bio, Inc. allow the company to explore the potential of engineered CAR T-cell therapies in refractory hematological cancer patients. The company’s anti-CD47 antibody targeting macrophage activity, CC-90002, is in phase I trials, being evaluated for the treatment of solid tumor cancers, multiple myeloma and AML. CC-90003, a covalent ERK inhibitor, is in a phase I trial targeting BRAF and RAS-mutated solid tumors. Cellular Therapies: At CCT (Celgene Cellular Therapeutics), the company is conducting research with stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the company’s research and development division dedicated to fulfilling the promise of cellular technologies by developing products and therapies to benefit patients. The company has developed proprietary technology for collecting, processing and storing placental stem cells with therapeutic applications in cancer, auto-immune diseases, and other inflammatory diseases. The company’s placental-derived, culture-expanded cellular therapy, PDA-002 (IM/SC injectable formulation), is in a phase II trial in patients with diabetic foot ulcers with and without peripheral artery disease and in a phase II trial for diabetic peripheral neuropathy. The company’s umbilical cord blood-derived, Natural Killer cell product PNK-007 is nearing phase I trials for the treatment of hematological malignancies, as an allogeneic cell therapy. The company also continues research to define the potential of placental-derived stem cells and to characterize other placental-derived products and other cell therapies. International Operations The company has operations outside the United States conducted both through its subsidiaries and through distributors. Distribution In most countries, the company promotes its products through its own sales organizations. In some countries, particularly in Latin America, the company partners with third-party distributors. The company distributes its products through commonly used channels in local markets. However, REVLIMID, POMALYST/IMNOVID and THALOMID/Thalidomide Celgene are distributed under mandatory risk-management distribution programs (such as REMS) tailored to meet local authorities' specifications to provide for their safe and appropriate distribution and use. Research and Development The company’s research and development expenses amounted to $3.697 billion in 2015. Patents As of December 31, 2015, the company owned or had licensed 644 issued U.S. patents and 596 additional pending U.S. patent applications. Patent term extensions have been granted in other markets for certain of the company’s patents related to REVLIMID. Patent term extensions for certain of the company’s patents related to lenalidomide have been granted in Europe, Australia, Korea, Japan and Russia. Further, patent term extensions for certain of its patents related to ABRAXANE have been secured and/or are being sought in Europe, Australia, Japan, Russia and Korea. The company is also considering alternative exclusivity strategies, mostly through international treaties, in various countries throughout Latin America. Governmental Regulation The company is subject to regulation under the Occupational Safety and Health Act; the Toxic Substances Control Act; the Resource Conservation and Recovery Act; and other federal, state and local laws, rules and regulations. Competition The company’s competitors include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms, including but not limited to: Hematology and Oncology: AbbVie Bahamas Ltd. and AbbVie Inc., Amgen, AstraZeneca PLC, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Merck, Novartis Pharma AG, Roche/Genentech, Sanofi and Takeda. Inflammation and Immunology: AbbVie Bahamas Ltd. and AbbVie Inc., Amgen, Biogen, Eisai, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Novartis Pharma AG, and UCB S.A. History Celgene Corporation was founded in 1980. The company was incorporated in the state of Delaware in 198
celgene corp (CELG:NASDAQ GS)
86 Morris Avenue
Summit, NJ 07901
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for CELG.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.